临床试验研究站点网路市场 - 全球产业规模、份额、趋势、机会及预测（按阶段、治疗领域、最终用户、地区和竞争格局划分，2021-2031年）

全球临床试验中心网路市场预计将从 2025 年的 89.2 亿美元成长到 2031 年的 142.5 亿美元，复合年增长率达到 8.12%。

该市场由集中管理的一体化研究机构组成，旨在更有效率地进行临床试验，为製药申办者提供跨区域、精简的试验中心选择、合约执行和病患招募服务。推动市场成长的关键因素包括：临床通讯协定日益复杂，需要专门的基础设施；以及对加速药物研发进程的需求。此外，研究的全球化需要健全的管理系统来确保合规性和数据一致性，这进一步凸显了一体化试验中心网路在跨国试验中的效用。

阻碍市场扩张的一大挑战是这些网络内各研究中心所面临的财务不稳定。许多研究中心都面临现金流波动和营运成本上升的双重困境，这威胁到它们的长期生存能力。根据临床研究中心协会（SCRS）预测，到2024年，50%的研究中心的营运资金将不到三个月。这种财务脆弱性限制了网路的扩充性，因为成员中心的资源限制和潜在的破产风险可能会阻碍临床试验的持续进行，并削弱网路提供可靠研究结果的整体能力。

市场驱动因素

製药和生物製药研发投入的不断增长，从根本上推动了全球临床试验中心网路市场的扩张，其原因在于所需研究的数量和规模都在不断扩大。随着生命科学公司加强投资以补充其药物研发管线，它们越来越依赖成熟的临床试验中心网络，以促进快速部署并确保跨多个地区的数据品质标准化。例如，默克在2024年2月发布的2023年度报告中揭露，其研发支出高达305亿美元，凸显了巨额资金流入对强大临床基础设施的迫切需求。这种投资激增推动了对整合式网路的需求，这些网路能够高效执行合同，并可即时接触到不同的患者群体，从而减轻申办方的行政负担，加速商业化进程。

随着临床试验设计和通讯协定日趋复杂，市场越来越依赖能够管理涉及众多终点、特殊生物标记和高级数据收集等复杂研究流程的成熟研究中心网络。如果没有集中资源，独立研究中心往往难以满足这些现代要求。事实上，临床研究专业人员协会 (ACRP) 在其 2024 年 10 月号的《临床研究员》杂誌中报告称，全球 70% 的临床实验中心工作人员认为，管理临床试验的难度远高于五年前。为了应对这些压力，研究中心网路能够提供必要的规模和专业培训，同时帮助克服效率瓶颈。例如，世界临床研究中心联盟 (WCG) 于 2024 年 10 月发布的《2024 年临床研究中心挑战报告》发现，35% 的研究中心认为「研究启动流程」是其面临的最大营运挑战。

市场挑战

单一研究中心的财务不稳定性对全球临床试验研究中心网路市场的成长构成重大障碍，因为这种经济脆弱性直接威胁到集中式网路向申办方承诺的可靠性和扩充性。当成员中心面临现金流波动或营运成本上升时，它们被迫优先考虑短期偿付能力而非长期能力建设。因此，网路在维持稳健的营运基础方面面临巨大阻力，因为单一成员中心的破产或资源减少都可能中断资料收集的连续性，并造成延误，从而损害网路模式价值提案的核心——效率。

这种岌岌可危的财务状况常常因付款延迟和通膨压力而加剧，从而削弱了研究中心营运的永续性。据临床研究中心协会（Society for Clinical Research Sites）称，与上年度相比，2024年将有34%的研究中心面临营运资金减少的情况。这种财务困境使研究中心无法投资必要的基础设施或留住熟练人员，从而削弱了整个网路的实力。如果没有财务状况良好的成员研究中心，网路市场将无法实现现代跨国临床试验所需的高效、一致的全球执行，从而阻碍研究中心网路模式的广泛应用。

市场趋势

随着投资者整合分散的研究机构并建立可扩展的平台，以建立集中管理的一体化网络，私募股权投资的兴起正在从根本上重塑市场格局。这一趋势提高了营运稳定性和议价能力，使网路能够升级基础设施，并确保复杂跨国试验所需的全球一致性执行。根据Fierce Biotech 2024年6月发表的一篇题为「私募股权投资试验基地」的文章，该领域正呈现持续成长势头，2023年的交易总额将比2017-2019年的记录高出50%。这证实了市场正朝向一体化、资本密集模式转变，这种模式能够有效解决独立机构的资源限制问题。

同时，随着各医疗机构整合机器学习技术，分析电子健康记录和真实世界数据，以消除长期存在的入组瓶颈，人工智慧驱动的患者招募解决方案的采用正在加速。这种技术变革使得在研究启动前能够准确、主动地识别合格的候选者，显着降低筛检失败率，并透过从被动的广告策略转向数据驱动的选择，加快研究进程。其益处显而易见。如同2024年9月《药学时报》题为「技术新前沿」的报导所述，在试点临床试验中整合人工智慧技术已将病患入组时间缩短了10-15%，使各医疗机构能够实现製药公司优先考虑的快速招募目标。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球临床试验研究中心网路市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 临床实验阶段（I期、II期、III期、IV期）
  • 依治疗领域（肿瘤科、心臟科、中枢神经系统疾病、疼痛管理、内分泌科、其他）
  • 依最终用户（製药/生物製药公司、医疗设备公司、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美临床试验研究中心网路市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲临床试验研究中心网路市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太地区临床试验研究中心网路市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲临床试验研究中心网路市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美临床试验研究中心网路市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球临床试验研究站点网路市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• ICON plc
• IQVIA Inc.
• Velocity Clinical Research Inc.
• Elligo Health Research, Inc.
• WCG Clinical, Inc.
• Access Clinical Trials Inc.
• FOMAT Medical Research, Inc.
• ClinChoice International
• SMO-Pharmina
• SGS Societe Generale de Surveillance SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Clinical Trial Investigative Site Network Market is projected to expand from USD 8.92 Billion in 2025 to USD 14.25 Billion by 2031, achieving a compound annual growth rate (CAGR) of 8.12%. This market consists of integrated research facilities that operate under a centralized administration to execute clinical studies with greater efficiency, offering pharmaceutical sponsors streamlined capabilities regarding site selection, contracting, and patient recruitment across various geographic regions. The primary factors driving market growth include the increasing complexity of clinical protocols, which demand specialized infrastructure, and the urgent need to expedite drug development timelines. Additionally, the globalization of research requires robust management systems to ensure regulatory compliance and data consistency, further validating the utility of consolidated site networks for multinational trials.

A major challenge hindering market expansion is the financial instability experienced by individual sites within these networks, as many facilities struggle with cash flow volatility and rising operational costs that threaten their long-term viability. According to the Society for Clinical Research Sites, 50% of research sites held three months or less of operating capital in 2024. This financial fragility limits the scalability of networks, as the resource constraints or potential insolvency of member sites can interrupt trial continuity and undermine the collective capacity of the network to deliver reliable research results.

Market Driver

Rising R&D expenditures in the pharmaceutical and biopharmaceutical sectors are fundamentally driving the expansion of the Global Clinical Trial Investigative Site Network Market by increasing both the volume and financial scale of required studies. As life science enterprises intensify their investments to replenish drug pipelines, they increasingly rely on established site networks to facilitate rapid deployment and ensure standardized data quality across multiple geographies. For example, Merck & Co. reported in its '2023 Annual Report' in February 2024 that research and development expenses reached $30.5 billion, highlighting the massive capital inflows that necessitate robust clinical infrastructure. This surge in investment fuels the demand for consolidated networks that offer streamlined contracting and immediate access to diverse patient pools, thereby reducing administrative burdens on sponsors and accelerating commercialization.

The growing complexity of clinical trial designs and protocols further propels market reliance on sophisticated site networks capable of managing intricate study procedures involving numerous endpoints, specialized biomarkers, and advanced data collection. Independent sites often struggle to support these modern requirements without centralized resources; in fact, the Association of Clinical Research Professionals reported in its 'Clinical Researcher' journal in October 2024 that 70% of global investigative site staff find clinical trials significantly more difficult to manage than they were five years ago. To address these pressures, site networks provide necessary scale and specialized training while helping to overcome efficiency hurdles, such as study start-up processes, which 35% of research sites identified as a top operational challenge in WCG's '2024 Clinical Research Site Challenges Report' from October 2024.

Market Challenge

The financial instability of individual research facilities constitutes a significant barrier to the growth of the Global Clinical Trial Investigative Site Network Market, as this economic fragility directly threatens the reliability and scalability that centralized networks promise to sponsors. When member sites are burdened by cash flow volatility and escalating operational costs, they are often forced to prioritize immediate solvency over long-term capacity building. Consequently, networks face substantial friction in maintaining a robust operational footprint, because the insolvency or resource contraction of even a single member site can disrupt the continuity of data collection, causing delays that negate the efficiency central to the network model's value proposition.

This precarious financial landscape is frequently exacerbated by payment delays and inflationary pressures that erode the viability of site operations. According to the Society for Clinical Research Sites, 34% of research sites experienced a decline in operating capital in 2024 compared to the previous year. Such financial erosion prevents facilities from investing in necessary infrastructure or retaining skilled personnel, thereby diminishing the collective strength of the network. Without financially sound member facilities, the network market struggles to deliver the streamlined, consistent global execution required for modern multinational trials, ultimately stalling the broader adoption of the site network model.

Market Trends

The rise of private equity investment is fundamentally restructuring the market as investors aggregate fragmented research facilities into scalable platforms to create integrated networks with centralized management. This trend enhances operational stability and negotiation leverage, enabling networks to upgrade infrastructure and ensure the consistent global execution necessary for complex multinational trials. According to an article in Fierce Biotech from June 2024 titled 'Private equity invests in trial sites', the sector has seen sustained momentum, with total deal activity in 2023 reaching levels 50% higher than those recorded between 2017 and 2019. This confirms the market's shift toward a consolidated, capital-intensive model that effectively addresses the resource limitations of standalone facilities.

Concurrently, the adoption of AI-driven patient recruitment solutions is accelerating as networks integrate machine learning to resolve persistent enrollment bottlenecks by analyzing electronic health records and real-world data. This technological pivot allows for the precise, proactive identification of eligible candidates before studies commence, replacing reactive advertising strategies with data-informed selection to significantly reduce screen failure rates and expedite timelines. The impact is measurable; as noted in the 'New Frontiers in Technology' article by Pharmacy Times in September 2024, the integration of AI technologies in pilot clinical trials resulted in a 10% to 15% reduction in patient enrollment times, enabling networks to deliver the accelerated recruitment speeds prioritized by pharmaceutical sponsors.

Key Market Players

• ICON plc
• IQVIA Inc.
• Velocity Clinical Research Inc.
• Elligo Health Research, Inc.
• WCG Clinical, Inc.
• Access Clinical Trials Inc.
• FOMAT Medical Research, Inc.
• ClinChoice International
• SMO-Pharmina
• SGS Societe Generale de Surveillance SA

Report Scope

In this report, the Global Clinical Trial Investigative Site Network Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trial Investigative Site Network Market, By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

Clinical Trial Investigative Site Network Market, By Therapeutic Area

• Oncology
• Cardiology
• CNS Conditions
• Pain Management
• Endocrine
• Others

Clinical Trial Investigative Site Network Market, By End User

• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others

Clinical Trial Investigative Site Network Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trial Investigative Site Network Market.

Available Customizations:

Global Clinical Trial Investigative Site Network Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Trial Investigative Site Network Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.2. By Therapeutic Area (Oncology, Cardiology, CNS Conditions, Pain Management, Endocrine, Others)
  • 5.2.3. By End User (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Clinical Trial Investigative Site Network Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Clinical Trial Investigative Site Network Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Therapeutic Area
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Clinical Trial Investigative Site Network Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Therapeutic Area
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Clinical Trial Investigative Site Network Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Therapeutic Area
      • 6.3.3.2.3. By End User

7. Europe Clinical Trial Investigative Site Network Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Clinical Trial Investigative Site Network Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Therapeutic Area
      • 7.3.1.2.3. By End User
  • 7.3.2. France Clinical Trial Investigative Site Network Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Therapeutic Area
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Clinical Trial Investigative Site Network Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Therapeutic Area
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Clinical Trial Investigative Site Network Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Therapeutic Area
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Clinical Trial Investigative Site Network Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Therapeutic Area
      • 7.3.5.2.3. By End User

8. Asia Pacific Clinical Trial Investigative Site Network Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Clinical Trial Investigative Site Network Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Therapeutic Area
      • 8.3.1.2.3. By End User
  • 8.3.2. India Clinical Trial Investigative Site Network Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Therapeutic Area
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Clinical Trial Investigative Site Network Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Therapeutic Area
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Clinical Trial Investigative Site Network Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Phase
      • 8.3.4.2.2. By Therapeutic Area
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Clinical Trial Investigative Site Network Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Phase
      • 8.3.5.2.2. By Therapeutic Area
      • 8.3.5.2.3. By End User

9. Middle East & Africa Clinical Trial Investigative Site Network Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Clinical Trial Investigative Site Network Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Therapeutic Area
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Clinical Trial Investigative Site Network Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Therapeutic Area
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Clinical Trial Investigative Site Network Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Therapeutic Area
      • 9.3.3.2.3. By End User

10. South America Clinical Trial Investigative Site Network Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Clinical Trial Investigative Site Network Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Therapeutic Area
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Clinical Trial Investigative Site Network Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Therapeutic Area
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Clinical Trial Investigative Site Network Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Therapeutic Area
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Clinical Trial Investigative Site Network Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ICON plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. IQVIA Inc.
• 15.3. Velocity Clinical Research Inc.
• 15.4. Elligo Health Research, Inc.
• 15.5. WCG Clinical, Inc.
• 15.6. Access Clinical Trials Inc.
• 15.7. FOMAT Medical Research, Inc.
• 15.8. ClinChoice International
• 15.9. SMO-Pharmina
• 15.10. SGS Societe Generale de Surveillance SA

16. Strategic Recommendations

17. About Us & Disclaimer